What is the current Price Target for the Structure Therapeutics stock?

The average Structure Therapeutics target price is $104.55. This is 190.26% higher than the current stock price. The highest price target is 322.68%, the lowest is 96.28%. 17 Analysts have issued a price target Structure Therapeutics 2027 .

How high will the Structure Therapeutics stock rise?

No reliable answer can be given as to how high the Structure Therapeutics stock will rise. The performance of stocks, including the Structure Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Structure Therapeutics stock today?

The performance of Structure Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Structure Therapeutics stock fall?

The decline in Structure Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Structure Therapeutics Forecast, price target & analysts

$36.02

0.19%

Nasdaq, Sep 24, 04:00 pm EDT. Closed.

ISIN

US86366E1064

Symbol

GPCR

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Analysts Charts Ownership News Strategies

Structure Therapeutics Target price 2026 - Analyst rating & recommendation

Structure Therapeutics Classifications & Recommendation

Buy

91%

Hold

Structure Therapeutics Price Target

Target Price	$104.55
Price	$36.02
Potential	190.26% register free of charge
Number of Estimates	17

	17 Analysts have issued a price target Structure Therapeutics 2027 . The average Structure Therapeutics target price is $104.55. This is 190.26% register free of charge higher than the current stock price. The highest price target is $152.25 322.68% register free of charge , the lowest is $70.70 96.28% register free of charge .
	A rating was issued by 23 analysts: 21 Analysts recommend Structure Therapeutics to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Structure Therapeutics stock has an average upside potential 2027 of 190.26% register free of charge . Most analysts recommend the Structure Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-0.80	-2.19
	2.56%	173.75%
P/E		negative

18 Analysts have issued a Structure Therapeutics forecast for earnings per share. The average Structure Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-0.80	2.56%
2026	$-2.19 173.75% unlock
2027	$-2.68 22.37% unlock
2028	$-2.30 14.18% unlock
2029	$0.57 124.78% unlock
2030	$2.18 282.46% unlock
2031	$4.59 110.55% unlock
2032	$7.33 59.69% unlock
2033	$10.20 39.15% unlock

Current	-46.18	103.68%
2026	-16.42 64.37% unlock
2027	-13.39 18.45% unlock
2028	-15.65 16.88% unlock
2029	63.50 505.75% unlock
2030	16.53 73.97% unlock
2031	7.83 52.63% unlock
2032	4.90 37.42% unlock
2033	3.52 28.16% unlock

Structure Therapeutics...

Current Structure Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citizens	Locked ➜ Locked	Locked	Sep 09 2026
Citigroup	Locked ➜ Locked	Locked	Aug 07 2026
Citizens	Locked ➜ Locked	Locked	Aug 07 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 11 2026
Canaccord Genuity	Locked ➜ Locked	Locked	Apr 27 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 16 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 02 2026

Analyst Rating	Date
Locked Citizens: Locked ➜ Locked	Sep 09 2026
Locked Citigroup: Locked ➜ Locked	Aug 07 2026
Locked Citizens: Locked ➜ Locked	Aug 07 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 11 2026
Locked Canaccord Genuity: Locked ➜ Locked	Apr 27 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 16 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 02 2026

Discover more stocks with a high price target

NIO ADR 101.75%

Alibaba Group Holding Ltd 67.67%

Tencent Holdings Ltd. 55.89%

Uber Technologies 48.83%

Siemens Energy 47.15%

Adidas 46.64%

BYD 44.49%

Deutsche Telekom 38.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now